Effect of biologic agents on regulatory T cells

Transplantation Reviews

Volumn 25, Issue 3, 2011, Pages 110-116

  De Serres, Sacha A ^a   Yeung, Melissa Y ^a   Mfarrej, Bechara G ^a   Najafian, Nader ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEFACEPT; ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; DACLIZUMAB; EFALIZUMAB; NATALIZUMAB; RAPAMYCIN; THYMOCYTE ANTIBODY;

DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW;

EID: 79959533187     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2010.11.002     Document Type: Review

References (74)

1. Sayegh M.H., Carpenter C.B. Transplantation 50 years later-progress, challenges, and promises. N Engl J Med 2004, 351:2761-2766.
2. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4:378-383.
3. Salama A.D., Remuzzi G., Harmon W.E., Sayegh M.H. Challenges to achieving clinical transplantation tolerance. J Clin Invest 2001, 108:943-948.
4. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
5. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
6. Levings M.K., Sangregorio R., Roncarolo M.G. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001, 193:1295-1302.
7. Cao D., Malmstrom V., Baecher-Allan C., Hafler D., Klareskog L., Trollmo C. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003, 33:215-223.
8. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199:971-979.
9. Coombes J.L., Robinson N.J., Maloy K.J., Uhlig H.H., Powrie F. Regulatory T cells and intestinal homeostasis. Immunol Rev 2005, 204:184-194.
10. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
11. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
12. Khattri R., Cox T., Yasayko S.A., Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4:337-342.
13. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007, 37:129-138.
14. Liu W., Putnam A.L., Xu-Yu Z., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-1711.
15. Seddiki N., Santner-Nanan B., Martinson J., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
16. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005, 6:338-344.
17. Tang Q., Henriksen K.J., Bi M., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004, 199:1455-1465.
18. Sanchez-Fueyo A., Sandner S., Habicht A., et al. Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol 2006, 176:329-334.
19. Klein L., Khazaie K., von Boehmer H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A 2003, 100:8886-8891.
20. Koenen H.J., Smeets R.L., Vink P.M., van Rijssen E., Boots A.M., Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
21. Strom T.B., Koulmanda M. Recently discovered T cell subsets cannot keep their commitments. J Am Soc Nephrol 2009, 20:1677-1680.
22. Degauque N., Mariat C., Kenny J., et al. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest 2008, 118:735-741.
23. Ueno T., Habicht A., Clarkson M.R., et al. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest 2008, 118:742-751.
24. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11:7-13.
25. Chen W., Jin W., Hardegen N., et al. Conversion of peripheral CD4+CD25+ naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
26. - cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004, 172:5213-5221.
27. De Serres S.A., Sayegh M.H., Najafian N. Immunosuppressive drugs and Tregs: a critical evaluation!. Clin J Am Soc Nephrol 2009, 4:1661-1669.
28. + precursors in a thymus-independent process. J Immunol 2004, 172:923-928.
29. Ochando J.C., Homma C., Yang Y., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006, 7:652-662.
30. Mantel P.Y., Ouaked N., Ruckert B., et al. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol 2006, 176:3593-3602.
31. Dunn C.J., Wagstaff A.J., Perry C.M., Plosker G.L., Goa K.L. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 2001, 61:1957-2016.
32. Lal G., Bromberg J.S. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009, 114:3727-3735.
33. Bonnefoy-Berard N., Vincent C., Revillard J.P. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991, 51:669-673.
34. Lopez M., Clarkson M.R., Albin M., Sayegh M.H., Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006, 17:2844-2853.
35. Feng X., Kajigaya S., Solomou E.E., et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25high FOXP3+ regulatory T cells in vitro. Blood 2008, 111:3675-3683.
36. + cells. Transplantation 2008, 86:1419-1426.
37. Agarwal S., Rao A. Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity 1998, 9:765-775.
38. +) T regulatory cells. Blood 2009, 114:5003-5006.
39. D'Addio F., Yuan X., Habicht A., et al. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. Transplantation 2010, 90:260-269.
40. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005, 80:457-465.
41. De Serres S.A., Mfarrej B.G., Grafals M., et al. Characterization of regulatory and effector T cells in renal transplant recipients after induction with Thymoglobulin vs. basiliximab: an interim report. J Am Soc Nephrol: (abstr) 2010.
42. Pascual J., Marcen R., Ortuno J. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab. Nephrol Dial Transplant 2001, 16:1756-1760.
43. Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296.
44. Burchill M.A., Yang J., Vogtenhuber C., Blazar B.R., Farrar M.A. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 2007, 178:280-290.
45. + cells in vitro. Am J Transplant 2005, 5:454-464.
46. Baan C.C., van Gelder T., Balk A.H., et al. Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection. Transplantation 2000, 69:331-336.
47. Bluestone J.A., Liu W., Yabu J.M., et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008, 8:2086-2096.
48. + regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008, 8:793-802.
49. Toso C., Edgar R., Pawlick R., et al. Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int 2009, 22:182-191.
50. + T regulatory cells. J Immunol 2006, 176:3301-3305.
51. Linsley P.S., Greene J.L., Brady W., Bajorath J., Ledbetter J.A., Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1:793-801.
52. Larsen C.P., Pearson T.C., Adams A.B., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005, 5:443-453.
53. + regulatory T cells. J Immunol 2003, 171:3348-3352.
54. Lohr J., Knoechel B., Abbas A.K. Regulatory T cells in the periphery. Immunol Rev 2006, 212:149-162.
55. Chavez H., Beaudreuil S., Abbed K., et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007, 17:243-248.
56. Grimbert P., Audard V., Diet C., et al. T-cell phenotype in protocol renal biopsy from transplant recipients treated with Belatacept-mediated co-stimulatory blockade. Nephrol Dial Transplant 2010, Jul 28. [Epub ahead of print].
57. Treumann A., Lifely M.R., Schneider P., Ferguson M.A. Primary structure of CD52. J Biol Chem 1995, 270:6088-6099.
58. + T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008, 8:338-347.
59. Noris M., Casiraghi F., Todeschini M., et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007, 18:1007-1018.
60. De Serres S., Najafian N., Mfarrej B.G., Benitez F., Sayegh M.H., Harmon W. Immunoprofiling after profound T cell depletion and minimization of immunosuppression in pediatric kidney transplantation: a study of CCTPT/NIAID. Am J Transplant 2010, 10:141. (abstr).
61. Pearl J.P., Parris J., Hale D.A., et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005, 5:465-474.
62. Rowan W.C., Hale G., Tite J.P., Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 1995, 7:69-77.
63. Ellis C.N., Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001, 345:248-255.
64. Vaishnaw A.K., TenHoor C.N. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 2002, 29:415-426.
65. Weaver T.A., Charafeddine A.H., Agarwal A., et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009, 15:746-749.
66. Stenner M.P., Waschbisch A., Buck D., et al. Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS ONE 2008, 3:e3319. 10.1371/journal.pone.0003319.
67. Sato T., Tachibana K., Nojima Y., D'Avirro N., Morimoto C. Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4. J Immunol 1995, 155:2938-2947.
68. Kivisakk P., Healy B.C., Viglietta V., et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009, 72:1922-1930.
69. Mortensen D.L., Walicke P.A., Wang X., et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 2005, 45:286-298.
70. Posselt A., Szot G., Frassetto L., et al. Islet allograft survival in type 1 diabetics using a calcineurin-free protocol based on efalizumab and sirolimus. Am J Transplant 2006, 8:235-236.
71. +) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001, 193:1311-1318.
72. Sanchez-Fueyo A., Weber M., Domenig C., Strom T.B., Zheng X.X. Tracking the immunoregulatory mechanisms active during allograft tolerance. J Immunol 2002, 168:2274-2281.
73. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
74. Ruggenenti P., Perico N., Gotti E., et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007, 84:956-964.